By Counterforce Health Team in Koselugo (selumetinib) —

How to Get Koselugo (Selumetinib) Covered by Humana in Washington: Complete Prior Authorization Guide

Quick Answer: Getting Koselugo Covered by Humana in Washington

Koselugo (selumetinib) requires prior authorization from Humana for pediatric patients ≥1 year with symptomatic, inoperable plexiform neurofibromas in neurofibromatosis type 1 (NF1). The fastest path: submit complete documentation including NF1 diagnosis (ICD-10: Q85.01), baseline LVEF assessment, and proof of inoperability through Humana's provider portal. If denied, Washington residents have strong appeal rights including external review through an Independent Review Organization (IRO). First step today: contact Onco360 specialty pharmacy (1-877-662-6633) to begin benefits verification while your provider prepares the prior authorization packet.

Table of Contents

  1. Who Should Use This Guide
  2. Member & Plan Basics
  3. Clinical Criteria Requirements
  4. Coding & Documentation
  5. Medical Necessity Letter Components
  6. Submission Process
  7. Specialty Pharmacy Coordination
  8. After Submission: What to Expect
  9. Common Denial Reasons & Fixes
  10. Washington Appeals Process
  11. Costs & Financial Support
  12. Frequently Asked Questions

Who Should Use This Guide

This guide is for families and healthcare providers seeking Humana coverage for Koselugo in pediatric NF1 patients with symptomatic plexiform neurofibromas. You'll need this if:

  • Your child has confirmed NF1 and symptomatic plexiform neurofibromas that can't be completely surgically removed
  • You have Humana Medicare Advantage or commercial insurance in Washington
  • Your provider has recommended Koselugo as treatment
  • You've received a denial and need to appeal

Expected outcome: With proper documentation, most medically appropriate Koselugo requests get approved. Humana's Medicare Advantage PA denial rate is approximately 3.5%—among the lowest of major insurers—and appeals are often successful when clinical criteria are clearly met.

Member & Plan Basics

Coverage Requirements

Requirement Details Verification
Active Coverage Current Humana member with prescription benefits Check member portal or ID card
Plan Type Medicare Part D or commercial pharmacy benefit Review Evidence of Coverage
Prior Authorization Required for all Koselugo prescriptions Humana PA search tool
Formulary Status Covered under specialty tier Verify on plan's drug list
Note: Koselugo is dispensed exclusively through Onco360 specialty pharmacy, which coordinates with Humana's network coverage.

Clinical Criteria Requirements

FDA-Approved Indication

Koselugo is approved for pediatric patients ≥1 year (expanded from ≥2 years in 2025) and adults with NF1 who have symptomatic, inoperable plexiform neurofibromas.

Step-by-Step Clinical Documentation

1. NF1 Diagnosis Confirmation

  • Genetic testing showing NF1 mutation OR
  • Clinical diagnosis meeting ≥2 NIH criteria:
    • ≥6 café-au-lait macules
    • ≥2 neurofibromas or 1 plexiform neurofibroma
    • Freckling in axillary or inguinal regions
    • Optic glioma
    • ≥2 Lisch nodules
    • Distinctive osseous lesion
    • First-degree relative with NF1

2. Plexiform Neurofibroma Requirements

  • Symptomatic: Document pain, disfigurement, or functional impairment
  • Inoperable: MRI evidence showing tumors not amenable to complete surgical resection
  • Progressive: Imaging showing growth or worsening symptoms

3. Safety Prerequisites

  • Baseline LVEF: Normal ejection fraction by echocardiogram
  • Ophthalmologic evaluation: Comprehensive eye exam to rule out retinopathy
  • Contraindication screening: Review for conditions precluding MEK inhibitor use

Coding & Documentation

ICD-10 Codes

  • Primary: Q85.01 (Neurofibromatosis, type 1)
  • Secondary: Site-specific codes for plexiform neurofibromas:
    • D36.10 (Peripheral nerves, unspecified)
    • D36.11 (Face, head, neck)
    • D36.12 (Upper limb)
    • D36.13 (Lower limb)
    • D36.14 (Thorax)
    • D36.15 (Abdomen)

NDC Codes

  • 10 mg capsules: 73065-201-30
  • 25 mg capsules: 73065-202-30
Important: Koselugo has no J-code or HCPCS code. It's billed under NDC codes as an oral specialty medication covered under Part D, not Part B.

Medical Necessity Letter Components

Essential Elements for Provider Letter

1. Patient Information

  • Age (≥1 year), weight, body surface area
  • NF1 diagnosis with supporting evidence
  • Plexiform neurofibroma location and symptoms

2. Clinical Rationale

  • FDA-approved indication met
  • Symptoms impacting quality of life
  • Surgical consultation confirming inoperability
  • No effective alternatives available

3. Safety Compliance

  • Normal baseline LVEF documented
  • Ophthalmologic clearance obtained
  • Monitoring plan established (LVEF every 3 months year 1, then every 6 months)

4. Supporting Evidence

  • Reference SPRINT trial showing 70% partial response rate
  • Cite FDA approval based on sustained tumor volume reduction
  • Include relevant imaging reports and surgical consultation notes

Submission Process

Fastest Path to Approval

1. Provider Preparation (Days 1-2)

  • Complete prior authorization form via Humana provider portal
  • Gather all required documentation
  • Submit baseline safety assessments

2. Benefits Verification (Day 1)

3. Submission (Day 3)

  • Submit complete packet through provider portal
  • Include all attachments in single submission
  • Request expedited review if medically urgent

4. Follow-up (Days 4-7)

  • Track status through provider portal
  • Respond promptly to any information requests
  • Prepare for potential peer-to-peer review

Required Documentation Checklist

  • Completed prior authorization form
  • Provider letter of medical necessity
  • NF1 diagnosis confirmation (genetic test or clinical criteria)
  • MRI reports showing plexiform neurofibromas
  • Surgical consultation confirming inoperability
  • Baseline echocardiogram (normal LVEF)
  • Ophthalmologic evaluation report
  • Previous treatment history (if applicable)

Specialty Pharmacy Coordination

Onco360 Exclusive Distribution

Koselugo is only available through Onco360 specialty pharmacy, which is covered under Humana's pharmacy policy. This exclusive arrangement streamlines the process:

Benefits of Onco360 Partnership:

  • Direct insurance verification and PA support
  • 24/7 oncology pharmacist access
  • Home delivery coordination
  • Financial assistance program enrollment

Contact Information:

  • Phone: 1-877-662-6633
  • Website: Onco360.com
  • Hours: 24/7 for urgent needs
Tip: Enroll with Onco360 immediately after prescription is written. They'll handle benefits verification while your provider submits the PA, potentially saving several days.

After Submission: What to Expect

Timeline Expectations

  • Standard PA decision: 15-30 business days
  • Expedited review: 72 hours (if medically urgent)
  • Peer-to-peer review: May be requested before denial

Status Monitoring

  • Check provider portal daily for updates
  • Document all confirmation numbers
  • Maintain communication with Onco360

Approval Process

Once approved, Onco360 will:

  1. Verify final insurance details
  2. Process prescription and arrange shipment
  3. Coordinate ongoing refills and monitoring
  4. Provide patient education and support

Common Denial Reasons & Fixes

Denial Reason Fix Strategy Required Documentation
Insufficient NF1 documentation Submit genetic testing or detailed clinical criteria Lab results or comprehensive clinical assessment
Missing safety assessments Provide baseline LVEF and eye exam Echocardiogram and ophthalmology reports
Question of medical necessity Emphasize FDA approval and symptom impact Updated provider letter with quality of life impact
Age restrictions Confirm current FDA approval for ≥1 year Reference updated prescribing information
Step therapy requirement Document lack of effective alternatives Literature showing no comparable treatments

Prevention Tips

  1. Submit complete packets: Incomplete submissions cause automatic denials
  2. Use current forms: Outdated PA forms are rejected
  3. Include imaging dates: Ensure MRI reports are recent (within 6 months)
  4. Specify symptoms: Generic "symptomatic" isn't sufficient—detail functional impact
  5. Confirm provider credentials: Ensure prescriber is appropriate specialist

Washington Appeals Process

Washington residents have robust appeal rights when Humana denies coverage. The state's external review process is among the strongest in the nation.

Internal Appeals (Required First Step)

Timeline: 65 days from denial notice Process: Submit through Humana member portal or by mail Decision timeframe: 30 days standard, 72 hours expedited

External Review (Independent Review Organization)

If internal appeals fail, Washington law provides access to independent review:

Who can request: Any Washington resident with a final internal denial Timeline: 180 days from final internal denial to request external review Process: Submit request to Washington Office of the Insurance Commissioner (OIC) or directly to Humana Decision timeframe: 30 days standard, 72 hours expedited

Washington OIC Consumer Advocacy: 1-800-562-6900

From our advocates: "We've seen families successfully overturn Koselugo denials in Washington by emphasizing the FDA approval and lack of alternatives in their external review submissions. The key is providing clear evidence that surgery isn't feasible and that symptoms significantly impact daily life. While outcomes vary by case, Washington's independent review process gives families a fair second opinion from medical experts who aren't employed by the insurance company."

Required Documents for Appeals

  • Copy of original denial letter
  • All medical records supporting the request
  • Updated provider letter addressing denial reasons
  • Patient impact statement (optional but helpful)

Costs & Financial Support

Estimated Costs

  • Retail price: Approximately $268,677 annually for pediatric dosing
  • Humana coverage: Varies by plan; typically specialty tier copay
  • Medicare Part D: $2,000 annual out-of-pocket maximum (2025)

Financial Assistance Options

For Commercial Insurance:

  • Koselugo Savings Program: May reduce copays to $0 (eligibility restrictions apply)
  • Alexion OneSource patient assistance programs

For Medicare Patients:

  • Medicare Extra Help (Low-Income Subsidy)
  • Medicare Prescription Payment Plan (spread costs monthly)
  • State pharmaceutical assistance programs
Note: Medicare beneficiaries are not eligible for manufacturer copay programs but may qualify for other assistance.

Frequently Asked Questions

How long does Humana prior authorization take for Koselugo? Standard PA decisions take 15-30 business days. Expedited reviews (for urgent medical situations) are completed within 72 hours.

What if Koselugo isn't on my Humana formulary? Even non-formulary drugs can be covered through formulary exceptions. Submit a medical necessity request emphasizing FDA approval and lack of alternatives.

Can I request an expedited appeal in Washington? Yes, if your health could be in serious jeopardy without the medication. Both internal and external reviews offer expedited options with 72-hour decision timeframes.

Does step therapy apply to Koselugo? Step therapy requirements vary by plan, but Koselugo's unique FDA indication (first approved treatment for NF1 plexiform neurofibromas) often exempts it from step therapy.

What happens if my child outgrows pediatric dosing? Adult patients with NF1 plexiform neurofibromas now have access to mirdametinib (Gomekli), FDA-approved in 2025 for both adults and children ≥2 years.

How do I coordinate between my local provider and Onco360? Onco360 handles coordination directly with your provider's office. Ensure both have current contact information and are enrolled in the Alexion OneSource program.

Counterforce Health helps patients, clinicians, and specialty pharmacies navigate complex prior authorization requirements by turning insurance denials into targeted, evidence-backed appeals. Our platform analyzes denial letters, plan policies, and clinical notes to identify the specific denial basis and draft point-by-point rebuttals aligned to each plan's requirements. For families facing Humana denials for medications like Koselugo, Counterforce Health provides the specialized expertise needed to build compelling appeals that address payer-specific workflows and procedural requirements.

For additional support with your Koselugo prior authorization or appeal, consider leveraging Counterforce Health's platform, which pulls the right evidence citations and weaves them into appeals with the required clinical facts, helping ensure cleaner submissions that reduce back-and-forth with insurers.

Sources & Further Reading

Disclaimer: This information is for educational purposes only and does not constitute medical or legal advice. Insurance coverage decisions depend on individual plan terms and medical circumstances. Always consult with your healthcare provider and insurance company for personalized guidance. For official appeals assistance in Washington, contact the Office of the Insurance Commissioner at 1-800-562-6900.

Powered by Counterforce Health—AI that turns drug denials into evidence-based appeals patients and clinicians can submit today.